Opyl Ltd. ( (AU:OPL) ) has provided an update.
Opyl Ltd. has introduced TrialKey, an AI-driven analysis tool that assesses 1,300+ variables to predict clinical trial success with over 92% accuracy, aiming to improve trial designs. This innovation positions the company to capitalize on a vast global market, offering significant opportunities in the pharmaceutical and medtech industries, where trial failures are common, potentially generating substantial revenue.
More about Opyl Ltd.
YTD Price Performance: -25.00%
Average Trading Volume: 274,030
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$2.89M
See more insights into OPL stock on TipRanks’ Stock Analysis page.